Fosamax Lawsuit

Information about Lawsuit's Relating To The Drug Fosamax

Fosamax Lawsuit - Information about Lawsuit's Relating To The Drug Fosamax


A number of Fosamax lawsuits seeking financial compensation have already been filed against Merck & Co. for injuries caused as a result of serious Fosamax side effects. The Fosamax side effect that has been singled out for legal action is the development of a serious bone condition called osteonecrosis of the jaw (ONJ), or “dead jaw.”

One of the first Fosamax lawsuits to be filed against Merck & Co. stems from a 60-year-old woman from Florida who was using the bisphosphonate drug to treat her osteoporosis. The lawsuit states that six-plus years of Fosamax treatments caused the woman to develop a severe case of ONJ, rotting her mouth and exposing bone in her jaw. Merck has been accused of withholding information regarding the serious nature of certain Fosamax side effects, notably the drug’s propensity towards causing the development of osteonecrosis of the jaw.

Thus far, an estimated 15 Fosamax lawsuits have been filed against Merck & Co. Although this may seem like a negligible number of personal injury lawsuits for a company as large as Merck & Co., experts believe that it is only the beginning and expect the filing of hundreds, if not thousands more claims as more cases of osteonecrosis come to light.

During the 1990s, the prescription drug Fosamax became a popular treatment for osteoporosis and other conditions that weaken bones. Sadly, many patients who were prescribed the drug have experienced serious complications such as bone fractures and osteonecrosis of the jaw (ONJ). The resulting injuries have sparked thousands of lawsuits against Merck, the drug’s maker.

Dangerous-drug cases are usually complicated. It’s a good idea to talk to a products liability lawyer if you have been injured by Fosamax.

An estimated 20 percent of American women over 50 develop osteoporosis. The condition affects men, too. So it is no surprise that Fosamax gained widespread popularity when Merck advertised it as limiting bone loss. The drug ultimately generated billions for Merck — and serious injuries for many patients. By 2006, Merck faced lawsuits across the United States over Fosamax injuries.